Float Short %

10.78

Margin Of Safety %

-27

Put/Call OI Ratio

0.48

EPS Next Q Diff

-3.17

EPS Last/This Y

4.82

EPS This/Next Y

-3.27

Price

15.93

Target Price

41.77

Analyst Recom

1.67

Performance Q

13.46

Relative Volume

0.84

Beta

0.95

Ticker: ARWR

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-07-07	ARWR	16.85	0.46	1.37	17750
2025-07-08	ARWR	17.54	0.48	0.03	18263
2025-07-09	ARWR	18.87	0.46	0.03	18689
2025-07-10	ARWR	18.87	0.45	0.46	19001
2025-07-11	ARWR	18.3	0.45	1.51	19130
2025-07-14	ARWR	18.61	0.46	0.11	19222
2025-07-15	ARWR	17.64	0.45	0.31	19483
2025-07-16	ARWR	18.29	0.45	0.02	19560
2025-07-17	ARWR	18.86	0.45	0.00	19619
2025-07-18	ARWR	16.75	0.44	1.47	19955
2025-07-21	ARWR	14.7	0.55	0.10	18064
2025-07-22	ARWR	14.97	0.43	0.22	23587
2025-07-23	ARWR	15.92	0.42	0.14	25004
2025-07-24	ARWR	16.26	0.42	1.53	26377
2025-07-25	ARWR	15.74	0.45	1.94	26942
2025-07-28	ARWR	16.2	0.46	0.16	27301
2025-07-29	ARWR	15.91	0.46	1.39	27612
2025-07-30	ARWR	15.7	0.47	0.46	27999
2025-07-31	ARWR	15.78	0.48	0.10	28419
2025-08-01	ARWR	15.92	0.48	0.20	28498
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-07-07	ARWR	16.84	20.2	-297.6	-0.18
2025-07-08	ARWR	17.54	20.2	-319.0	-0.18
2025-07-09	ARWR	18.88	20.2	-337.6	-0.18
2025-07-10	ARWR	18.86	20.2	-295.4	-0.18
2025-07-11	ARWR	18.31	20.2	-280.0	-0.18
2025-07-14	ARWR	18.62	20.2	-305.0	-0.18
2025-07-15	ARWR	17.63	20.2	-268.0	-0.18
2025-07-16	ARWR	18.28	20.2	-316.0	-0.18
2025-07-17	ARWR	18.85	20.2	-312.1	-0.18
2025-07-18	ARWR	16.76	20.2	-237.3	-0.18
2025-07-21	ARWR	14.71	20.2	-228.0	-0.18
2025-07-22	ARWR	14.95	20.2	-305.8	-0.18
2025-07-23	ARWR	15.92	20.2	-333.4	-0.18
2025-07-24	ARWR	16.26	20.2	-308.1	-0.18
2025-07-25	ARWR	15.74	20.2	-277.9	-0.18
2025-07-28	ARWR	16.23	20.2	-313.5	-0.18
2025-07-29	ARWR	15.92	20.2	-286.3	-0.18
2025-07-30	ARWR	15.70	20.2	-288.3	-0.18
2025-07-31	ARWR	15.80	20.2	-299.3	-0.18
2025-08-01	ARWR	15.93	20.2	-300.5	-0.18
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-07-07	ARWR	-2.59	5.24	11.01
2025-07-08	ARWR	-2.11	5.24	11.01
2025-07-09	ARWR	-2.11	5.24	11.01
2025-07-10	ARWR	-2.11	5.24	11.01
2025-07-11	ARWR	-2.11	5.24	10.95
2025-07-14	ARWR	-2.11	5.36	10.95
2025-07-15	ARWR	-2.11	5.36	10.95
2025-07-16	ARWR	-2.11	5.36	10.95
2025-07-17	ARWR	-2.11	5.36	10.95
2025-07-18	ARWR	-2.11	5.36	10.95
2025-07-21	ARWR	-2.11	5.40	10.95
2025-07-22	ARWR	-2.11	5.40	10.95
2025-07-23	ARWR	-2.11	5.40	10.95
2025-07-24	ARWR	-2.11	5.40	10.95
2025-07-25	ARWR	-2.11	5.40	10.78
2025-07-28	ARWR	-2.11	5.10	10.78
2025-07-29	ARWR	-2.11	5.10	10.78
2025-07-30	ARWR	-2.11	5.10	10.78
2025-07-31	ARWR	-2.11	5.10	10.78
2025-08-01	ARWR	-2.11	5.10	10.78
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

2.75

Avg. EPS Est. Current Quarter

-1.1

Avg. EPS Est. Next Quarter

-0.42

Insider Transactions

-2.11

Institutional Transactions

5.1

Beta

0.95

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

115

Fair Value

11.58

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-89

Target Price

41.77

P/E

Forward P/E

PEG

P/S

4.04

P/B

3.22

P/Free Cash Flow

478.25

EPS

-1.38

Average EPS Est. Cur. Y

-0.18

EPS Next Y. (Est.)

-3.45

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-26.41

Relative Volume

0.84

Return on Equity vs Sector %

-44.8

Return on Equity vs Industry %

-26.2

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

-300.5

Arrowhead Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 609

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.

stock quote shares ARWR – Arrowhead Pharmaceuticals, Inc. Stock Price stock today

news today ARWR – Arrowhead Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch ARWR – Arrowhead Pharmaceuticals, Inc. yahoo finance google finance

stock history ARWR – Arrowhead Pharmaceuticals, Inc. invest stock market

stock prices ARWR premarket after hours

ticker ARWR fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ARWR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y